Is CGEN a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Compugen (CGEN) rests on Rilvegostomig royalties at AstraZeneca: The largest long-term value driver is a drug Compugen does not run. The bear case rests on the biggest risk is that the TIGIT class does not work well enough. Analysts covering it publish targets from $4.00 to $6.00 against a $1.84 share price on November 20, 2026, so even the professionals disagree by 42% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CGEN key stats
At $1.84 on November 20, 2026, Compugen (CGEN) has a market cap of $174M and a P/E of 4.7 on trailing earnings.
- Market cap
- $174M
- P/E (trailing)
- 4.7
- EPS (trailing 12 months)
- $0.39
- Price to book
- 2.1
- Beta
- 2.82
Market cap, P/E and yield are measured at the $1.84 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Compugen (CGEN)?
The last two weeks for Compugen, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- CGEN closed at $1.84 on November 20, 2026, down 12.4% over the past five trading days (from $2.10).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Compugen Ltd. is a clinical-stage immuno-oncology company based in Holon, Israel, listed on Nasdaq and the Tel Aviv Stock Exchange. Its edge has always been computational: a predictive discovery platform used to find new drug targets in the immune system. That platform produced the antibodies behind its pipeline. COM701 is a first-in-class antibody against PVRIG, which Compugen develops itself. COM902, an anti-TIGIT antibody, is the source of the TIGIT arm of rilvegostomig, the PD-1/TIGIT bispecific that AstraZeneca licensed and now runs in about 12 Phase 3 trials. GS-0321 (formerly COM503), an antibody that blocks IL-18 binding protein, was licensed to Gilead in late 2024 and is in Phase 1 dose escalation. The financials read strangely because almost all revenue comes from partners. In 2025 Compugen reported ~$72.8 million of revenue and ~$35.3 million of net profit, but that was driven by a one-time $65 million payment from AstraZeneca in December 2025 for a slice of future rilvegostomig royalties, with up to $25 million more on BLA acceptance. Strip that out and the run rate is small. Q3 2026, reported November 9, brought revenue of ~$3.8 million, about double the ~$1.9 million of a year earlier and above estimates, from recognized Gilead payments; R&D was ~$5.8 million, G&A ~$2.3 million and the net loss ~$5.8 million, or $0.06 per share, better than the ~$0.09 consensus. Cash, deposits and securities were ~$117.5 million at September 30, 2026, down from ~$145.6 million at year end, with no meaningful debt and management still guiding to a runway into 2029. The investment picture is a sum of parts trading at a discount. At ~$1.84 and ~94.6 million shares, the equity is worth ~$174 million, so the market assigns roughly ~$57 million to everything beyond the cash pile. That modest number reflects history: several big-pharma TIGIT programs were dropped after disappointing trials, which colors how investors view rilvegostomig. The near-term swing factor is COM701's MAIA-ovarian trial, a randomized, placebo-controlled maintenance study in relapsed platinum-sensitive ovarian cancer that is now fully enrolled with 62 patients randomized 2:1, with results guided by the end of Q1 2027. For rilvegostomig, AstraZeneca's first Phase 3 readout, ARTEMIDE-Biliary01 in 760 biliary tract cancer patients, is now expected in the second half of 2027. The shares closed at ~$1.84 on November 20, 2026, up ~19% year to date and ~21% over one year but down ~36% over three months, which suggests patience is wearing thin ahead of those readouts.
The bull case: what would have to be true for $6.00
The most optimistic published target on CGEN is $6.00, +226.1% from the $1.84 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Rilvegostomig royalties at AstraZeneca
The largest long-term value driver is a drug Compugen does not run. AstraZeneca's rilvegostomig combines PD-1 blockade with a TIGIT arm derived from Compugen's COM902, and AstraZeneca has expanded it into about 12 Phase 3 trials across lung, biliary tract, gastric, urothelial and other cancers, including a newly started combination with Datroway in urothelial cancer. At ASCO 2026, the GEMINI-Hepatobiliary study showed a ~16.8 month median overall survival in first-line biliary tract cancer, the drug's first OS readout. Compugen keeps the majority of its tiered royalties (up to mid-single digits) after the December 2025 sale, plus remaining milestones and a potential ~$25 million payment on BLA acceptance. AstraZeneca reported Phase 2 ARTEMIDE-01 overall survival data in September 2026 that compared favorably with historical controls, and the first Phase 3 result, ARTEMIDE-Biliary01 in 760 biliary tract cancer patients, is now expected in the second half of 2027. Compugen is eligible for up to ~$195 million in additional milestones, with most Phase 3 readouts coming in 2027 and later.
2. COM701 and the MAIA-ovarian readout
COM701 is Compugen's wholly owned, first-in-class anti-PVRIG antibody, and MAIA-ovarian is the company's most important in-house test. The trial evaluates COM701 as a maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer, a setting where patients often have limited options once PARP inhibitors are used up. The design is randomized and placebo-controlled, which makes the result cleaner than the single-arm data that earlier PVRIG work relied on. Enrollment is complete, with 62 patients randomized 2:1 to COM701 or placebo across sites in the U.S., Israel and France, and management guides to results by the end of Q1 2027. A small trial gives a fast answer but leaves room for noise. A clear signal could support partnering talks; a miss would leave Compugen mainly a royalty holder.
3. Gilead and GS-0321 milestones
In December 2024 Gilead licensed COM503, now GS-0321, an antibody designed to block IL-18 binding protein so that the immune system's own IL-18 can act inside tumors. Compugen received a ~$60 million upfront payment and a ~$30 million milestone when the IND cleared in 2025, and it is eligible for up to roughly ~$758 million in further development, regulatory and commercial milestones, plus tiered royalties. The Phase 1 dose-escalation study is progressing under Gilead's control. Compugen still recognizes portions of those earlier payments as revenue, which is why quarterly revenue runs at ~$2 million to ~$3 million, and it carried ~$31.8 million of deferred revenue at mid-2026. Q3 2026 revenue of ~$3.8 million came from the same source, and no new milestone was reported in the quarter.
4. Cash runway and a cheap enterprise value
Compugen's balance sheet is unusual for a small biotech. Cash, deposits and marketable securities were ~$117.5 million at September 30, 2026, against a market cap near ~$174 million and minimal debt, leaving an enterprise value of roughly ~$57 million. Quarterly cash burn has been running around ~$7 million to ~$10 million, and management says current funds cover operations into 2029 without any further inflows. That matters because it means the company can reach the MAIA-ovarian results and the first rilvegostomig Phase 3 readout without needing to raise equity at depressed prices. Any new milestone from AstraZeneca or Gilead would extend that runway further. In October 2026 Compugen also introduced UnigenX, an extension of its AI discovery platform aimed at finding tumor-associated antigens for T cell engagers and similar formats, a possible source of future partner deals.
The bear case: what would have to be true for $4.00
The most pessimistic published target is $4.00, +117.4% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Compugen is worth if the risks below bite instead of the drivers above.
The biggest risk is that the TIGIT class does not work well enough. Roche, Merck and others discontinued TIGIT programs after disappointing late-stage results, and if rilvegostomig's Phase 3 trials follow that path, the royalty stream that underpins much of Compugen's value could shrink toward zero. Compugen also has no control over AstraZeneca's or Gilead's priorities, timelines or decisions to cut programs. COM701 is a single binary event: MAIA-ovarian, with only 62 patients, could show no meaningful benefit, and PVRIG has never been validated in a randomized trial. Rilvegostomig's first Phase 3 readout has also moved to the second half of 2027. Revenue is irregular and partner-driven, so headline profit in 2025 says little about the underlying business, which lost ~$5.8 million in Q3 2026 and ~$6 million to ~$8 million in earlier quarters. Having already sold part of its rilvegostomig royalties, Compugen has given up some upside in exchange for cash today. The stock traded at ~$1.84 on November 20, 2026, after a ~36% three-month fall, a level where Nasdaq's $1 minimum bid rule has bitten before (Compugen regained compliance in January 2024 after falling below it). As an Israeli company, it also carries currency and regional geopolitical exposure, and thin trading can make the shares move sharply on small news. Finally, if MAIA-ovarian succeeds, a larger registrational trial would cost far more than today's burn, which could mean dilution or a partnership on less favorable terms.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CGEN already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CGEN
5 analysts cover CGEN, with an average target of $4.80 (+160.9% against $1.84) and a split of 5 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CGEN forecast and price target page.
How is CGEN valued?
Market cap, P/E and dividend yield at today's price are in the CGEN key stats above. The business figures below come from Compugen's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$76 million (incl. ~$65 million one-time royalty sale); Q3 2026 ~$3.8 million
- Net income (TTM): ~$36 million (one-time driven); Q3 2026 loss ~$5.8 million
- Cash and investments: ~$117.5 million (September 30, 2026), minimal debt
- Enterprise value: ~$57 million
As of November 2026: Traditional ratios do not describe Compugen well. The trailing P/E of ~4.7 looks cheap only because trailing revenue and profit include the ~$65 million December 2025 royalty sale to AstraZeneca; the recurring business generates ~$2 million to ~$4 million of revenue a quarter and a loss of ~$6 million to ~$8 million. The more useful lens is enterprise value: at ~$1.84 per share, the market places roughly ~$57 million on the pipeline above cash, about 2.1 times book equity. The five analysts tracked by Yahoo Finance have a mean target near $4.80 with a strong buy consensus, but for a company like this, valuation moves on trial data and partner news, not on quarterly earnings, so the cash balance and the burn rate are the figures that tend to anchor the share price between catalysts.
How do you decide if CGEN is a buy?
Whether CGEN is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CGEN indirectly through an index or sector ETF before adding more.
What would change your mind on CGEN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Rilvegostomig royalties at AstraZeneca stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the biggest risk is that the TIGIT class does not work well enough fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CGEN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CGEN against your real portfolio and see your actual exposure before deciding.
Your questions about Compugen
Ask Walnut's AI anything about CGEN and see how it fits what you own.
FAQ
Is CGEN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Rilvegostomig royalties at AstraZeneca, with revenue (ttm) at ~$76 million (incl. ~$65 million one-time royalty sale); Q3 2026 ~$3.8 million. The bear case rests on the biggest risk is that the TIGIT class does not work well enough. Analysts covering it are spread from $4.00 to $6.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CGEN?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest risk is that the TIGIT class does not work well enough. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $4.00, +117.4% from the $1.84 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for CGEN?
+
Rilvegostomig royalties at AstraZeneca. The largest long-term value driver is a drug Compugen does not run. The most optimistic analyst target on CGEN is $6.00, +226.1% from the $1.84 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CGEN?
+
The biggest risk is that the TIGIT class does not work well enough. Roche, Merck and others discontinued TIGIT programs after disappointing late-stage results, and if rilvegostomig's Phase 3 trials follow that path, the royalty stream that underpins much of Compugen's value could shrink toward zero. Compugen also has no control over AstraZeneca's or Gilead's priorities, timelines or decisions to cut programs. COM701 is a single binary event: MAIA-ovarian, with only 62 patients, could show no meaningful benefit, and PVRIG has never been validated in a randomized trial. Rilvegostomig's first Phase 3 readout has also moved to the second half of 2027. Revenue is irregular and partner-driven, so headline profit in 2025 says little about the underlying business, which lost ~$5.8 million in Q3 2026 and ~$6 million to ~$8 million in earlier quarters. Having already sold part of its rilvegostomig royalties, Compugen has given up some upside in exchange for cash today. The stock traded at ~$1.84 on November 20, 2026, after a ~36% three-month fall, a level where Nasdaq's $1 minimum bid rule has bitten before (Compugen regained compliance in January 2024 after falling below it). As an Israeli company, it also carries currency and regional geopolitical exposure, and thin trading can make the shares move sharply on small news. Finally, if MAIA-ovarian succeeds, a larger registrational trial would cost far more than today's burn, which could mean dilution or a partnership on less favorable terms. The most pessimistic published target is $4.00, +117.4% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Compugen do?
+
Israeli cancer immunotherapy biotech with drugs partnered to AstraZeneca and Gilead.
What would have to change for CGEN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Rilvegostomig royalties at AstraZeneca) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the biggest risk is that the TIGIT class does not work well enough) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Compugen do?
+
Compugen is a clinical-stage biotech in Holon, Israel, that uses a computational discovery platform to find new immune checkpoint targets and then builds antibodies against them. It has three programs that matter today. COM701, an antibody against PVRIG, is wholly owned and in a randomized ovarian cancer trial. The TIGIT component of AstraZeneca's rilvegostomig came from Compugen's COM902, so Compugen earns milestones and royalties on that drug. GS-0321, an IL-18 binding protein blocker, is licensed to Gilead and in Phase 1. The company has no marketed products, so all of its revenue comes from license, milestone and royalty-related payments from those two partners.
Why did Compugen report a profit in 2025?
+
Compugen reported ~$72.8 million of revenue and ~$35.3 million of net profit for 2025, but nearly all of that came from one transaction. In December 2025 it sold a portion of its future rilvegostomig royalties back to AstraZeneca for $65 million upfront, with up to $25 million more if a BLA is accepted. It also booked a $5 million clinical milestone from AstraZeneca and recognized portions of Gilead payments. Without the royalty sale, the business ran at a loss. In 2026, quarterly revenue fell back to ~$2 million to ~$4 million, and net losses returned, at ~$5.8 million to ~$7.7 million per quarter. The 2025 profit is a one-time event, not a trend.
How much cash does Compugen have?
+
At September 30, 2026, Compugen held ~$117.5 million in cash, cash equivalents, short-term bank deposits and marketable securities, with minimal debt. That was down from ~$125.3 million at June 30 and ~$145.6 million at the end of 2025, the result of roughly ~$8 million to ~$10 million of quarterly burn. Management says that balance funds its operating plans into 2029, assuming no further inflows. Against a market cap near ~$174 million at ~$1.84 per share (November 20, 2026), cash represents about two thirds of the company's equity value, which is why the enterprise value is only around ~$57 million.
Walnut is informational, not investment advice, and gives no verdict on CGEN. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.